NEWS DETAIL

Update of Significant Participations After the Expansion of Non-Monetary Capital

Pangea Oncology, S.A. (hereinafter, "Pangea" or the "Company"), in compliance with the provisions of article 17 of Regulation (EU) No. 596/2014 on market abuse and article 228 of the consolidated text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and concordant provisions, as well as in Circular 6/2018 of the Mercado AlternativoBursátil (MAB), makes available to the market the following information:

After the last non-monetary capital increase by offsetting credits made by the Company, which consisted of the issuance of 2,437,998 new shares that were subscribed and paid by Hersol XXI, S.L., we proceed to update information on significant holdings:

Shareholder                                   % indirect     % direct     % total
Hersol XXI, S.L.                                                    32.25%    
32.25%
Global Portfolio Investments, S.L.                        11.46%     11.46%
Biosense, S.L.                                                      10.17%     10.17%

List of shareholders with significant participation in Pangea (≥ 10%)

The following list of shareholders1 with a position equal to or greater than 10% in the share capital of Pangea is hereby communicated:

1 Those shareholders with a position equal to or greater than 10% who meet the condition of administrators and / or directors are excluded, which will be included in the following section to avoid unnecessary repetitions.

List of administrators and / or managers with significant participation (≥ 1%) in Pangea:

Counselor                                          % indirect     % direct     % total
Grupopikolin, S.L.                                                    17.23%     
17.23%
Topgenetics, S.L.                                                     10.77%      10.77%
Biolifepat, S.L.                                                          3.85%       
3.85%
Maectorax, S.L.U.                                                    
3.85%        3.85%
D. Javier Rivela Rodríguez                      9.66%2                       
9.66%
D. Rafael Rosell Costa                            6.46%3                       
6.46%
D. José Antonio Maestre Alcácer             3.85%4                       
3.85%
D. Santiago Ramón y Cajal Agüeras       2.31%5                        2.31%

Likewise, the following list of directors and / or managers with a position equal to or greater than 1% in the share capital of Pangea is disclosed:

2 Indirect participation held by Mr. Javier Rivela Rodríguez, CEO of Pangea, as a result of his direct 95% participation in Biosense, S.L.
3 Indirect participation held by Mr. Rafael Rosell Costa, as a result of his direct participation of 60% in Topgenetics, S.L.
4 Indirect participation held by Mr. José Antonio Maestre Alcácer, as a result of his direct participation of 100% in Maectorax, S.L.U.
5 Indirect participation held by Mr. Santiago Ramón y Cajal Agüeras, as a result of his direct participation of 60% in Biolifepat, S.L.

The Company is not aware of the existence of other shareholders with a position equal to or greater than 10% of the share capital, or of other directors and / or managers with a position equal to or greater than 1%.

We remain at your disposal for any clarifications deemed appropriate.